claim: treatment of the ccl5/rantes-ccr5 pathway restores immune homeostasis and reduces plasma viral load in critical covid-19
evidence_1: here, in 10 terminally-ill, critical covid-19 patients we report profound elevation of plasma il-6 and ccl5 (rantes), decreased cd8+ t cell levels, and sars-cov-2 plasma viremia.", "following compassionate care treatment with the ccr5 blocking antibody leronlimab, we observed complete ccr5 receptor occupancy on macrophage and t cells, rapid reduction of plasma il-6, restoration of the cd4/cd8 ratio, and a significant decrease in sars-cov-2 plasma viremia.", "these results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing sars-cov-2 plasma viral load via disruption of the ccl5-ccr5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of ccr5 for covid-19."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )